First-line standard of care outside of clinical trials is currently stratified by tumour and patient characteristics, taking into account the presence or absence of BRAF mutation, with recently published literature on treatment sequencing, supporting the sequencing of immunotherapy prior to BRAF inhibitors for less aggressive tumours [12, 13]. Here, BRAF is linked to neoplasm.